Skip to main content
. 2005 Oct 6;102(42):15195–15200. doi: 10.1073/pnas.0505114102

Fig. 5.

Fig. 5.

Depletion or mutation of the FBW7 tumor suppressor enhances DR5-A sensitivity in tumor-derived cell lines in a MYC-dependent manner. (a) The colon carcinoma-derived cell line, HCT116, was transfected with the indicated siRNAs as previously described, and sensitivity to DR5-A was compared with genetically engineered HCT116 cells (see Methods) heterozygous (+/-) or homozygous (-/-) for FBW7. Confirmation of the efficacy of siRNA-mediated knockdown and of FBW7 genotypic status is shown in Fig. 9. (b) HCT116 FBW7-/- cells were transfected with siRNAs and analyzed as in a with lower DR5-A concentrations (see Fig. 12 for comparison with higher DR5-A concentrations). (c) HCT116 FBW7+/+, FBW7+/-, and FBW7-/- cells were transfected with control siRNAs (siGL3), two distinct nonoverlapping siRNAs targeting MYC (siMYC1 and siMYC2), and an siRNA specific for cyclin E (siCyclinE). After 48 h, transfected cells were treated with DR5-A for 20 h, and cell viability was determined.